Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
АТХ:C.01.E.X Other combination drugs for the treatment of heart disease
Pharmacodynamics:Binds phosphates in the digestive tract, reduces their concentration in the blood serum. Does not cause hypercalcemia. The effect on the concentration of phosphorus in the blood is preserved when taking the drug for 1 year.
Pharmacokinetics:It is not absorbed into the digestive tract, but it is impossible to completely exclude the possible systemic absorption and cumulation during long-term use.
Indications:Prevention of hyperphosphataemia in CRF in patients on hemodialysis (as part of complex therapy, including preparations of Ca2 +, colcalciferol or analogs thereof).
XIV.N17-N19.N18.9 Chronic renal failure, unspecified
XIV.N17-N19.N18 Chronic Renal Failure
Contraindications:Hypersensitivity, hypophosphatemia, intestinal obstruction, simultaneous administration with ciprofloxacin, children and adolescence under 18 years.
Carefully:Side effects often occur in patients in the terminal stage of chronic renal failure.
Inflammatory bowel diseases, gastrointestinal motility disorder (including constipation), surgical operations on the gastrointestinal tract (in the anamnesis), pregnancy, lactation.
Pregnancy and lactation:The category of FDA recommendations is not defined.
Qualitative controlled studies in animals and humans were not conducted. There is no information on the penetration into breast milk.
Dosing and Administration:Inside, with food. Tablets are swallowed whole (without chewing).
For patients who did not receive drugs that bind phosphates: 800 mg 3 times a day (at a phosphate concentration of 1.76-2.42 mmol / l); 1600 mg 3 times a day (at a phosphate concentration of more than 2.42 mmol / l).
For patients receiving drugs, phosphate binders (preparations of Ca2 +): appointed in equivalent doses in terms of 1 mg of preparations containing Ca2 + (on the basis), which the patient took earlier.
The dose varies from 800 to 4000 mg, the maximum daily dose is 7 g.
The dose is selected taking into account the concentration of phosphates in the blood serum (the required decrease to 1.76 mmol / l and below). The phosphate concentration is monitored every 2-3 weeks until stabilization is achieved.
Side effects:From the digestive system: very often - nausea, vomiting, pain in the abdominal cavity, constipation, diarrhea, indigestion; often - flatulence.
From the side of the central nervous system: very often - a headache.
From the CCC: very often - an increase or decrease in blood pressure.
From the skin: very often - itching; often - a rash.
Others: very often - pain of different localization; often pharyngitis.
Interaction:Reduces the bioavailability of ciprofloxacin by 50%.
Special instructions:C caution should be used for inflammatory bowel diseases, gastrointestinal motility disorders (including constipation), for surgical operations on the digestive tract (in the anamnesis).
The concentration of phosphates is monitored every 2-3 weeks. before achieving their stabilization.
Medicines for which a decrease in bioavailability may be of clinical importance should be applied 1 hour before or 3 hours after taking sevelamer.